RT Journal Article SR Electronic T1 Exploration of Alzheimer’s Disease MRI Biomarkers Using APOE4 Carrier Status in the UK Biobank JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.09.09.21263324 DO 10.1101/2021.09.09.21263324 A1 Du, Jingnan A1 Liu, Zhaowen A1 Hanford, Lindsay C. A1 Anderson, Kevin M. A1 Feng, Jianfeng A1 Ge, Tian A1 Buckner, Randy L. YR 2021 UL http://medrxiv.org/content/early/2021/09/14/2021.09.09.21263324.abstract AB Large-scale datasets enable novel strategies to refine and discover relations among biomarkers of disease. Here 30,863 individuals ages 44-82 from the UK Biobank were analyzed to explore MRI biomarkers associated with Alzheimer’s disease (AD) genetic risk as contrast to general effects of aging. Individuals homozygotic for the E4 variant of apolipoprotein E (APOE4) overlapped non-carriers in their 50s but demonstrated neurodegenerative effects on the hippocampal system beginning in the seventh decade (reduced hippocampal volume, entorhinal thickness, and hippocampal cingulum integrity). Phenome-wide exploration further nominated the posterior thalamic radiation (PTR) as having a strong effect, as well as multiple diffusion MRI (dMRI) and white matter measures consistent with vascular dysfunction. Effects on the hippocampal system and white matter could be dissociated in the homozygotic APOE4 carriers supporting separation between AD and cerebral amyloid angiopathy (CAA) patterns. These results suggest new ways to combine and interrogate measures of neurodegeneration.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Simons Foundation grant 811255, NIH grants R01MH124004, P50MH106435, R00AG054573, and Shared Instrumentation Grant S10OD020039.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human subjects: UK Biobank has approval from the North West Multi-centre Research Ethics Committee (MREC) to obtain and disseminate data and samples from the participants (http://www.ukbiobank.ac.uk/ethics/), and these ethical regulations cover the work in this study. Written informed consent was obtained from all participants. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data analyzed in this study were provided by UK Biobank under application reference 32568. A description of the procedure to access the UK Biobank data is available at: http://www.ukbiobank.ac.uk/using-the-resource/.